


February 16, 2017



✓ **BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalai Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

**Dear Sir/Madam,**

**Sub: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

We are pleased to inform you that the Company has received USFDA approval for ANDA Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution (Syrup), 5 mg/1.5 mg per 5 mL, Generic of Hycodan® Oral Solution, 5 mg/1.5 mg per 5 mL, of Endo Pharmaceuticals, Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,  
For **LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)